PCYC up +2.15% percent Today $PCYC High is at 138.58 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
PCYC up +2.15% percent Today $PCYC High is at 138.58 and the Low 135.23 with current volume of 73,519.

Recent News posted below.

Pharmacyclics Inc PCYC other info.
http://investorshangout.com/Pharmacyclics-Inc-PCYC-55069/

PCYC Pharmacyclics Inc Recent Headline News

Pharmacyclics Earnings Hindsight: Up 2.6% in Last 13 Days (PCYC)
Comtex SmarTrend(R) - Mon Nov 17, 2:57PM CST
A week ago on November 4th, 2014 Pharmacyclics (NASDAQ CYC) reported earnings and analysts, on average, expected earnings of $0.44 on sales of $201.3 million. The company actually reported EPS of $0.69 on sales of $207.1 million, beating EPS estimates by $0.25 and beating revenue estimates by $5.8 million. Since the company's report, shares of Pharmacyclics have risen from $131.00 to $134.43, representing a gain of 2.6% in the past 13 days.
PCYC: 137.99 (+2.89)

Pharmacyclics Set to Possibly Pullback After Yesterday's Rally of 2.29%
Comtex SmarTrend(R) - Wed Nov 12, 4:38PM CST
Pharmacyclics (NASDAQ CYC) traded in a range yesterday that spanned from a low of $133.66 to a high of $139.25. Yesterday, the shares gained 2.3%, which took the trading range above the 3-day high of $136.11 on volume of 797,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PCYC: 137.99 (+2.89)

Uptrend Call Working As Pharmacyclics Stock Rises 18.2% (PCYC)
Comtex SmarTrend(R) - Wed Nov 12, 11:12AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on October 21st, 2014 at $115.55. In approximately 3 weeks, Pharmacyclics has returned 18.21% as of today's recent price of $136.58.
PCYC: 137.99 (+2.89)

Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.80 (-0.01), CRIS: 1.32 (+0.01), IMMU: 3.88 (+0.09), PCYC: 137.99 (+2.89), ONCY: 0.75 (+0.02), PFE: 30.57 (+0.25), LLY: 67.96 (+0.67), BMY: 58.70 (+0.27), GSK: 46.22 (+0.34), JNJ: 108.98 (+0.68), SNTA: 3.29 (+0.06), NVS: 95.48 (+1.10), XLRN: 34.71 (+1.51), ARRY: 3.75 (+0.12), CELGZ: 3.18 (-0.03), EXEL: 1.78 (+0.02)

Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig
Todd Campbell, The Motley Fool - Motley Fool - Fri Nov 07, 12:42PM CST
Source: Pharmacyclics Peak sales forecasts for Pharmacyclics'   Imbruvica are estimated north of $3 billion, but investors had reason for pause last quarter when competitor Gilead Sciences launched Zydelig for the same indication. ...
JNJ: 108.99 (+0.69), PCYC: 137.99 (+2.89), GILD: 102.07 (+1.63), AZN: 73.48 (+0.98), GSK: 46.21 (+0.33), BMY: 58.70 (+0.27), CELG: 106.66 (+2.30)

Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.27 (-0.01), PCYC: 137.99 (+2.89), CLDX: 17.45 (-0.80), INCY: 70.17 (+0.47), BIND: 10.31 (-0.09), CELG: 106.66 (+2.30), OMER: 20.91 (+1.17), VSTM: 9.06 (+0.06), GILD: 102.07 (+1.63), OGXI: 2.18 (-0.02), ANTH: 1.82 (unch), NVAX: 5.00 (+0.10)

Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 67.24 (+1.51), JNJ: 108.99 (+0.69), PCYC: 137.99 (+2.89), SHPG: 208.92 (+2.93), MRK: 59.78 (+0.32), AMGN: 160.44 (+1.30)

After Yesterday's Rally of 4.65% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 4:27PM CST
Pharmacyclics (NASDAQ CYC) traded in a range yesterday that spanned from a low of $130.29 to a high of $137.42. Yesterday, the shares gained 4.6%, which took the trading range above the 3-day high of $136.89 on volume of 1.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PCYC: 137.99 (+2.89)

IMBRUVICA® (ibrutinib) Data to be Presented Across Multiple Histologies, Including in Eight Oral Presentations, at 2014 American Society of Hematology (ASH) Annual Meeting
PR Newswire - Thu Nov 06, 8:09AM CST
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced a broad array of new IMBRUVICA® (ibrutinib) data across multiple histologies will be presented at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, CA from December 6 - 9, 2014. IMBRUVICA clinical and pre-clinical data will be featured in at least 37 abstracts, of which 17 are from company-sponsored clinical and non-clinical studies. Eight abstracts were selected for oral presentation.
PCYC: 137.99 (+2.89)

Keith Lui Joins Versartis to Lead Global Marketing Efforts
GlobeNewswire - Thu Nov 06, 7:42AM CST
Versartis, Inc. (Nasdaq:VSAR), an endocrine-focused biopharmaceutical company that is developing VRS-317, a novel, long-acting form of recombinant human growth hormone (rhGH) for the treatment of growth hormone deficiency (GHD), today announced that Keith L. Lui has joined the company as Vice President, Marketing. Mr. Lui will report to Versartis Chief Executive Officer Jeffrey L. Cleland, PhD, to lead the development and execution of the brand marketing process including global marketing launch plan activities for the Company's lead product candidate, VRS-317.
VSAR: 19.27 (+0.48), PCYC: 137.99 (+2.89)

Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 305.42 (+3.00), PCYC: 137.99 (+2.89), PSTI: 2.66 (-0.04), NBS: 5.23 (-1.55), ALDR: 16.89 (+0.03), IDRA: 2.42 (+0.04), SGEN: 37.79 (+1.94), JAZZ: 169.26 (-0.23), ALXN: 190.22 (+3.44), KMDA: 3.39 (+0.08), ATHX: 1.40 (+0.03), NVS: 95.48 (+1.10)

Pharmacyclics Tops Q3 Earnings, Ties Up with AstraZeneca - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:00AM CST
Pharmacyclics, Inc. (PCYC) reported third-quarter 2014 earnings (including stock-based compensation expenses) of 53 cents per share, above the Zacks Consensus Estimate of 45 cents.
JNJ: 108.99 (+0.69), PCYC: 137.99 (+2.89), AZN: 73.48 (+0.98), AMAG: 36.16 (+1.40)

Pharmacyclics Shares Up 14.1% Since SmarTrend's Buy Recommendation (PCYC)
Comtex SmarTrend(R) - Wed Nov 05, 10:01AM CST
SmarTrend identified an Uptrend for Pharmacyclics (NASDAQ CYC) on October 21st, 2014 at $115.55. In approximately 2 weeks, Pharmacyclics has returned 14.08% as of today's recent price of $131.81.
PCYC: 137.99 (+2.89)

Pharmacyclics' (PCYC) CEO Robert Duggan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 04, 8:01PM CST

PCYC: 137.99 (+2.89)

Pharmacyclics tops Street 3Q forecasts
Automated Insights - Tue Nov 04, 3:30PM CST
SUNNYVALE, Calif. (AP) _ Pharmacyclics Inc. (PCYC) on Tuesday reported third-quarter net income of $41.4 million.
PCYC: 137.99 (+2.89)

Pharmacyclics beats by $0.16, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 3:21PM CST

PCYC: 137.93 (+2.83)

Pharmacyclics Reports Third Quarter 2014 Financial Results and Provides Clinical Program Update
PR Newswire - Tue Nov 04, 3:05PM CST
Pharmacyclics, Inc. (the "Company" (NASDAQ: PCYC) today reported financial results for the third quarter and nine months ended September 30, 2014, as well as commercial, regulatory and clinical updates.
PCYC: 137.93 (+2.83)

AstraZeneca And Pharmacyclics Enter Clinical Trial Collaboration To Evaluate IMBRUVICA® In Hematologic Cancers
PR Newswire - Tue Nov 04, 1:32PM CST
AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate novel combination therapies targeting a number of hematologic cancers.
PCYC: 137.93 (+2.83)

AstraZeneca And Pharmacyclics Enter Immuno-Oncology Clinical Trial Collaboration With IMBRUVICA® In Solid Tumors
PR Newswire - Tue Nov 04, 10:00AM CST
AstraZeneca and Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that they have entered into a clinical trial collaboration to evaluate a novel combination therapy targeting solid tumors.
PCYC: 137.93 (+2.83)

AstraZeneca teams up with Pharmacyclics and Janssen in cancer combo
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 8:28AM CST

JNJ: 108.98 (+0.68), PCYC: 137.93 (+2.83), AZN: 73.48 (+0.98)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 154

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Docusign Pushes Contract Data Into ChatGPT Sales Tools

Updated Category News Views 187

Contracts are where sales momentum goes to get lost, buried under old PDFs, approval chains, and somebody’s half-finished CRM note. Docusign’s November 17, 2026 launch is a sensible attempt to drag that information into the place sellers may increasingly spend their working day: ChatGPT for Sales. The company’s new plugin lets a sales rep pull agreement intelligence...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
ELEGOO's Formnext Push Tests a Broader 3D Ambition

Updated Category News Views 123

Frankfurt’s show floor is where product promises meet some very unforgiving eyeballs. ELEGOO arrived at Formnext 2026 with more than a refreshed machine or two: it is laying out a wider bet across resin printing, FDM printing, and 3D scanning. That matters because the company is no longer presenting itself as merely a supplier of affordable creator hardware. It wants to...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 172

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 107

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 68

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 74

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Lab USA's Earnings Predictions and Market Insights

Updated Category News Views 157

Earned Expectations from Rocket Lab USA Rocket Lab USA (NASDAQ: RKLB) is gearing up for its quarterly earnings report, anticipated by investors with curiosity and optimism. The forthcoming announcement promises to deliver crucial insights into the company's financial health and growth trajectory. Expected Earnings Snapshot Analysts forecast that Rocket Lab will register...

Continue Reading
Upcoming Q2 Financial Results Announcement from Parkland

Updated Category News Views 108

Exciting News from Parkland Corporation Parkland Corporation, known for its dedication to providing quality fuel and convenience products, is gearing up for its next financial milestone. The company anticipates unveiling its second quarter results for 2025, a pivotal moment for investors and stakeholders alike. Key Announcement Details Scheduled to be disclosed after the...

Continue Reading
FLSmidth Secures Major Flotation Technology Contract for Iron Ore

Updated Category News Views 201

FLSmidth Secures Major Flotation Technology Contract for Iron Ore A leading Indian miner and steel producer has made a significant decision by selecting FLSmidth & Co. A/S to deliver a comprehensive flotation technology package for their state-of-the-art iron ore beneficiation plant. This facility is poised to be among the largest and most efficient of its kind globally,...

Continue Reading
Arthur J. Gallagher & Co. Plans Financial Results Conference

Updated Category News Views 118

Arthur J. Gallagher & Co. Announces Key Earnings Details Arthur J. Gallagher & Co. (NYSE: AJG) is gearing up to share its financial results for the fourth quarter of 2025. The announcement will be made after market closure on Thursday, January 29, 2026. Following this release, interested investors will find a printer-friendly version on the company’s official website,...

Continue Reading
Exelixis Faces Investor Scrutiny Amid Financial Reporting Concerns

Updated Category News Views 234

Exelixis under Investigation by Pomerantz Law Firm Pomerantz LLP, a renowned law firm, has initiated an investigation concerning investors of Exelixis, Inc. (NASDAQ: EXEL). This inquiry focuses on potential securities fraud or other unlawful practices involving the company and its leadership. Insights into Recent Financial Performance Recently, Exelixis reported its...

Continue Reading